The Recall Desk
CriticalFDA (Drugs)·D-0152-2018·Announced 2018-01-10

Fresenius Kabi Recalls Mislabelled Midazolam Syringes Containing Ondansetron

Fresenius Kabi is recalling 203,136 syringes of Midazolam Injection that were mislabeled and actually contain Ondansetron Injection.

What this means for you

Highest-severity recall. Risk of serious injury or death is documented or strongly suspected. Stop using the product now and follow the agency's instructions.

Our severity reasoning: The FDA has classified this recall as Class I, which meets the rubric criteria for a Critical severity score.

Plain-English summary

Fresenius Kabi USA, LLC is recalling 203,136 syringes of Midazolam Injection, USP, Preservative Free, 2 mg / 2 mL (1 mg / mL). The product is packaged in 24 x 2 mL prefilled single-use syringes per carton and is distributed nationwide in the USA. The specific lot number is 6400048.

The recall was initiated due to a labeling mix-up. The blister packages are labeled as Midazolam Injection, USP, 2 mg / 2 mL, but they actually contain syringes of Ondansetron Injection, USP, 4 mg / 2 mL. This discrepancy means that healthcare providers or patients relying on the label may administer the wrong medication.

Healthcare facilities and consumers who have this product should stop using it and contact Fresenius Kabi USA, LLC for instructions on how to return the product. The FDA has classified this recall as Class I, indicating a reasonable probability that use of the product may cause serious adverse health consequences or death.

The recalled product

Product
MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE)
Brand
MIDAZOLAM
Affected units
203,136

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • Lot: 6400048

Distribution

Distributed nationwide across the United States.

Same manufacturer · Fresenius Kabi USA, LLC

See all →